XuanZhu Bio-B (02575) Surges Over 7% Again as Piroxiclib Tablet Enters National Reimbursement List, Expected to Greatly Enhance Accessibility

Stock News01-08

XuanZhu Bio-B (02575) surged more than 7% again. As of the time of writing, the stock was up 6.95%, trading at HKD 58.45, with a turnover of HKD 10.7671 million. On the news front, on December 7, 2025, the National Healthcare Security Administration announced the results of the 2025 National Reimbursement Drug List adjustment. Piroxiclib Tablets, a Class 1 innovative drug and CDK4/6 inhibitor independently developed by XuanZhu Bio, were successfully included in the list, bringing new reimbursement benefits for patients with advanced breast cancer. Starting January 1, 2026, the national reimbursement for Piroxiclib officially takes effect, which is expected to significantly improve the drug's accessibility and effectively reduce the financial burden on patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124645799?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 15:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124645799","market":"hk","top_or_hot":-1,"title":"XuanZhu Bio-B (02575) Surges Over 7% Again as Piroxiclib Tablet Enters National Reimbursement List, Expected to Greatly Enhance Accessibility","media":"Stock News","content":"<p>XuanZhu Bio-B (02575) surged more than 7% again. As of the time of writing, the stock was up 6.95%, trading at HKD 58.45, with a turnover of HKD 10.7671 million. On the news front, on December 7, 2025, the National Healthcare Security Administration announced the results of the 2025 National Reimbursement Drug List adjustment. Piroxiclib Tablets, a Class 1 innovative drug and CDK4/6 inhibitor independently developed by XuanZhu Bio, were successfully included in the list, bringing new reimbursement benefits for patients with advanced breast cancer. Starting January 1, 2026, the national reimbursement for Piroxiclib officially takes effect, which is expected to significantly improve the drug's accessibility and effectively reduce the financial burden on patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XuanZhu Bio-B (02575) Surges Over 7% Again as Piroxiclib Tablet Enters National Reimbursement List, Expected to Greatly Enhance Accessibility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanZhu Bio-B (02575) Surges Over 7% Again as Piroxiclib Tablet Enters National Reimbursement List, Expected to Greatly Enhance Accessibility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-08 15:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XuanZhu Bio-B (02575) surged more than 7% again. As of the time of writing, the stock was up 6.95%, trading at HKD 58.45, with a turnover of HKD 10.7671 million. On the news front, on December 7, 2025, the National Healthcare Security Administration announced the results of the 2025 National Reimbursement Drug List adjustment. Piroxiclib Tablets, a Class 1 innovative drug and CDK4/6 inhibitor independently developed by XuanZhu Bio, were successfully included in the list, bringing new reimbursement benefits for patients with advanced breast cancer. Starting January 1, 2026, the national reimbursement for Piroxiclib officially takes effect, which is expected to significantly improve the drug's accessibility and effectively reduce the financial burden on patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1124645799","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124645799","pubTimestamp":1767856717,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"XuanZhu Bio-B (02575) surged more than 7% again. As of the time of writing, the stock was up 6.95%, trading at HKD 58.45, with a turnover of HKD 10.7671 million. On the news front, on December 7,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B","BK1191":"制药"},"translate_title":"轩竹生物-B(02575)再涨超7%，吡罗昔布片进入国家报销目录，有望大大增强可及性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"XuanZhu Bio-B (02575) surged more than 7% again. As of the time of writing, the stock was up 6.95%, trading at HKD 58.45, with a turnover of HKD 10.7671 million. On the news front, on December 7, 2025, the National Healthcare Security Administration announced the results of the 2025 National Reimbursement Drug List adjustment. Piroxiclib Tablets, a Class 1 innovative drug and CDK4/6 inhibitor independently developed by XuanZhu Bio, were successfully included in the list, bringing new reimbursement benefits for patients with advanced breast cancer. Starting January 1, 2026, the national reimbursement for Piroxiclib officially takes effect, which is expected to significantly improve the drug's accessibility and effectively reduce the financial burden on patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124645799","isCrawlerRequest":true}